190 related articles for article (PubMed ID: 31509242)
1. Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma.
Chow W; Frankel P; Ruel C; Araujo DM; Milhem M; Okuno S; Hartner L; Undevia S; Staddon A
Cancer; 2020 Jan; 126(1):105-111. PubMed ID: 31509242
[TBL] [Abstract][Full Text] [Related]
2. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.
Stacchiotti S; Ferrari S; Redondo A; Hindi N; Palmerini E; Vaz Salgado MA; Frezza AM; Casali PG; Gutierrez A; Lopez-Pousa A; Grignani G; Italiano A; LeCesne A; Dumont S; Blay JY; Penel N; Bernabeu D; de Alava E; Karanian M; Morosi C; Brich S; Dagrada GP; Vallacchi V; Castelli C; Brenca M; Racanelli D; Maestro R; Collini P; Cruz J; Martin-Broto J
Lancet Oncol; 2019 Sep; 20(9):1252-1262. PubMed ID: 31331701
[TBL] [Abstract][Full Text] [Related]
3. Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.
Samuels BL; Chawla SP; Somaiah N; Staddon AP; Skubitz KM; Milhem MM; Kaiser PE; Portnoy DC; Priebat DA; Walker MS; Stepanski EJ
Cancer; 2017 Dec; 123(23):4640-4647. PubMed ID: 28832986
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
Martin-Broto J; Stacchiotti S; Lopez-Pousa A; Redondo A; Bernabeu D; de Alava E; Casali PG; Italiano A; Gutierrez A; Moura DS; Peña-Chilet M; Diaz-Martin J; Biscuola M; Taron M; Collini P; Ranchere-Vince D; Garcia Del Muro X; Grignani G; Dumont S; Martinez-Trufero J; Palmerini E; Hindi N; Sebio A; Dopazo J; Dei Tos AP; LeCesne A; Blay JY; Cruz J
Lancet Oncol; 2019 Jan; 20(1):134-144. PubMed ID: 30578023
[TBL] [Abstract][Full Text] [Related]
5. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
Sternberg CN; Davis ID; Deen KC; Sigal E; Hawkins RE
Oncology; 2014; 87(6):342-50. PubMed ID: 25227656
[TBL] [Abstract][Full Text] [Related]
6. Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study.
Adkins D; Mehan P; Ley J; Siegel MJ; Siegel BA; Dehdashti F; Jiang X; Salama NN; Trinkaus K; Oppelt P
Lancet Oncol; 2018 Aug; 19(8):1082-1093. PubMed ID: 30001987
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).
Iwamoto FM; Lamborn KR; Robins HI; Mehta MP; Chang SM; Butowski NA; Deangelis LM; Abrey LE; Zhang WT; Prados MD; Fine HA
Neuro Oncol; 2010 Aug; 12(8):855-61. PubMed ID: 20200024
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of pazopanib in patients with metastatic or unresectable chemoresistant sarcomas: A Japanese Musculoskeletal Oncology Group study.
Urakawa H; Kawai A; Goto T; Hiraga H; Ozaki T; Tsuchiya H; Nakayama R; Naka N; Matsumoto Y; Kobayashi E; Okuma T; Kunisada T; Ando M; Ueda T; Nishida Y
Cancer Sci; 2020 Sep; 111(9):3303-3312. PubMed ID: 32579783
[TBL] [Abstract][Full Text] [Related]
9. Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis.
Katz D; Azraq Y; Eleyan F; Gill S; Peretz T; Merimsky O
BMC Cancer; 2016 Aug; 16():616. PubMed ID: 27501793
[TBL] [Abstract][Full Text] [Related]
10. Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma.
Jones RL; Katz D; Loggers ET; Davidson D; Rodler ET; Pollack SM
Med Oncol; 2017 Aug; 34(10):167. PubMed ID: 28852958
[TBL] [Abstract][Full Text] [Related]
11. Pazopanib-Induced Liver Toxicity in Patients With Metastatic Renal Cell Carcinoma: Effect of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety, and Patient Outcomes.
Henriksen JN; Bøttger P; Hermansen CK; Ladefoged SA; Nissen PH; Hamilton-Dutoit S; Fink TL; Donskov F
Clin Genitourin Cancer; 2020 Feb; 18(1):62-68.e2. PubMed ID: 31640912
[TBL] [Abstract][Full Text] [Related]
12. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
Monk BJ; Mas Lopez L; Zarba JJ; Oaknin A; Tarpin C; Termrungruanglert W; Alber JA; Ding J; Stutts MW; Pandite LN
J Clin Oncol; 2010 Aug; 28(22):3562-9. PubMed ID: 20606083
[TBL] [Abstract][Full Text] [Related]
13. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.
Toulmonde M; Pulido M; Ray-Coquard I; Andre T; Isambert N; Chevreau C; Penel N; Bompas E; Saada E; Bertucci F; Lebbe C; Le Cesne A; Soulie P; Piperno-Neumann S; Sweet S; Cecchi F; Hembrough T; Bellera C; Kind M; Crombe A; Lucchesi C; Le Loarer F; Blay JY; Italiano A
Lancet Oncol; 2019 Sep; 20(9):1263-1272. PubMed ID: 31331699
[TBL] [Abstract][Full Text] [Related]
14. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
Mir O; Cropet C; Toulmonde M; Cesne AL; Molimard M; Bompas E; Cassier P; Ray-Coquard I; Rios M; Adenis A; Italiano A; Bouché O; Chauzit E; Duffaud F; Bertucci F; Isambert N; Gautier J; Blay JY; Pérol D;
Lancet Oncol; 2016 May; 17(5):632-41. PubMed ID: 27068858
[TBL] [Abstract][Full Text] [Related]
16. Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study.
Grünwald V; Karch A; Schuler M; Schöffski P; Kopp HG; Bauer S; Kasper B; Lindner LH; Chemnitz JM; Crysandt M; Stein A; Steffen B; Richter S; Egerer G; Ivanyi P; Zimmermann S; Liu X; Kunitz A
J Clin Oncol; 2020 Oct; 38(30):3555-3564. PubMed ID: 32840417
[TBL] [Abstract][Full Text] [Related]
17. Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors.
Nishida Y; Urakawa H; Nakayama R; Kobayashi E; Ozaki T; Ae K; Matsumoto Y; Tsuchiya H; Goto T; Hiraga H; Naka N; Takahashi S; Ando Y; Ando M; Kuwatsuka Y; Hamada S; Ueda T; Kawai A
Int J Cancer; 2021 Jan; 148(1):140-149. PubMed ID: 32638374
[TBL] [Abstract][Full Text] [Related]
18. The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review.
Sneed GT; Lee S; Brown JN; Hammond JM
Clin Genitourin Cancer; 2019 Dec; 17(6):419-424. PubMed ID: 31585694
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
Fu S; Hou MM; Naing A; Janku F; Hess K; Zinner R; Subbiah V; Hong D; Wheler J; Piha-Paul S; Tsimberidou A; Karp D; Araujo D; Kee B; Hwu P; Wolff R; Kurzrock R; Meric-Bernstam F
Ann Oncol; 2015 May; 26(5):1012-1018. PubMed ID: 25669829
[TBL] [Abstract][Full Text] [Related]
20. Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma.
Subbiah V; Meyer C; Zinner R; Meric-Bernstam F; Zahurak ML; O'Connor A; Roszik J; Shaw K; Ludwig JA; Kurzrock R; Azad NA
Clin Cancer Res; 2017 Aug; 23(15):4027-4034. PubMed ID: 28377484
[No Abstract] [Full Text] [Related]
[Next] [New Search]
